S. Rowe
12 Papers
S. Rowe is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 12 publications.
Chat about Author
Papers
Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study.
S. Rowe,Jonathan B. Zuckerman,Daniel Dorgan,Jorge Lascano,Karen McCoy,Munendra Jain,Michael S. Schechter,Sherstin T. Lommatzsch,Veronica M Indihar,Noah Lechtzin,Kimberly McBennett,C.J. Brown,Theodore G. Liou,Katie Macdonald,Samya Z. Nasr,Susan Bodie,Meagan F Vaughn,Eric B. Meltzer,Ann J. Barbier +18 more
TL;DR: In this paper , a randomized, double-blind, placebo-controlled Phase 1/2 study performed in the US was conducted, where participants with 2 severe class I and/or II CFTR mutations and baseline ppFEV1 values between 50 and 90% were randomized 3:1 (MRT5005: placebo).
53
Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study.
Nicole Mayer-Hamblett,E. Zemanick,Katherine Odem-Davis,Donald R. VanDevanter,Mark Warden,S. Rowe,J. Young,M. Konstan,for-the-CHEC-SC-Study-Group +8 more
TL;DR: The CHEC-SC as mentioned in this paper is an ongoing epidemiologic study characterizing modulator-induced sweat chloride (SC) responses across the CF population, with interim results available prior to the availability of triple combination modulator therapy.
7
155 Longitudinal improvements in clinical and functional outcomes following initiation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis
K. Vijaykumar,HY Leung,Á. Barrios,Samantha Donaldson,D Nichols,S. Rowe,Gary Tearney,G. Solomon +7 more
TL;DR: Treatment with ELX/TEZ/IVA in people with CF, including those that were treatment naive and those on prior modulator therapy, resulted in significant, sustained improvement in lung function and decreases in sweat chloride levels at ~10 months, consistent with recently published reports.
137 Tobacco smoke exposure reduces the clinical efficacy of ivacaftor: Results from the G551D Observational Trial
TL;DR: This study used urinary biomarkers of second-hand smoke exposure to examine its effect on ivacaftor response in participants in the G551D Observational Trial (GOAL), and designed and developed the CF Early- onset Lung disease scoring system by using prospectively collected longitudinal data on pulmonary disease manifestations in the first 3 years of life.
EPS5.02 Faecal microbiota changes in patients with cystic fibrosis with 6 months of elexacaftor/tezacaftor/ivacaftor: preliminary findings from the PROMISE study
Jennifer T. Duong,Christopher E. Pope,Hillary S. Hayden,Carl Maximilian Miller,Declan Raftery,Stephen J. Salipante,J. Pittman,Friederike Ratjen,Margaret Rosenfeld,S. Rowe,G. Solomon,D Nichols,Lj Hoffman +12 more
TL;DR: The interplay between fecal dysbiosis, fecal BA content, and markers of GI function and inflammation is not well studied in CF patients as mentioned in this paper , but it is known that patients with CF often have higher BA content and increased fecal inflammation and altered BA.